Key Takeaways:
Argus on May 13 maintained its neutral rating on Novo Nordisk (NVO) and a price target of $46.73.
Morningstar also maintained its bullish rating on the stock in a May 6 report.
The average analyst price target for NVO is $46.73, with a high estimate of $64.20 and a low of $39.57. The stock has a recommendation rating of 2.36, where 1 is Strong Buy and 5 is Sell.
The maintained price target from Argus suggests the firm sees the company as fairly valued at current levels. Investors will be watching for any changes in analyst sentiment following the company's next earnings report.
This article is for informational purposes only and does not constitute investment advice.
